{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:20Z","timestamp":1786988120892,"version":"build-2736575974"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/136892\/2018"],"award-info":[{"award-number":["SFRH\/BD\/136892\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/148771\/2019"],"award-info":[{"award-number":["SFRH\/BD\/148771\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI050875"],"award-info":[{"award-number":["R01AI050875"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI121700"],"award-info":[{"award-number":["R21AI121700"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejpb.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T06:22:56Z","timestamp":1676010176000},"page":"214-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Nanodelivery systems for cutaneous melanoma treatment"],"prefix":"10.1016","volume":"184","author":[{"given":"Irina","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Pereira-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salette","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cl\u00e1udia","family":"Paiva-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.02.002_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2014.11.001","article-title":"Skin cancer and new treatment perspectives: a review","volume":"357","author":"Simoes","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2023.02.002_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0702a01","article-title":"Epidemiological trends in skin cancer","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol. Pract. Concept"},{"key":"10.1016\/j.ejpb.2023.02.002_b0015","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1101\/gad.1437206","article-title":"Malignant melanoma: genetics and therapeutics in the genomic era","volume":"20","author":"Chin","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejpb.2023.02.002_b0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-018-0732-8","article-title":"The world of melanoma: epidemiologic, genetic, and anatomic differences of melanoma across the globe","volume":"20","author":"Dimitriou","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejpb.2023.02.002_b0025","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1586\/era.10.170","article-title":"A new understanding in the epidemiology of melanoma","volume":"10","author":"Erdei","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejpb.2023.02.002_b0030","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"10.1016\/j.ejpb.2023.02.002_b0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-319-22539-5_2","article-title":"Melanoma epidemiology and prevention","volume":"167","author":"Berwick","year":"2016","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0040","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1751-1097.2007.00283.x","article-title":"Role of UV in cutaneous melanoma","volume":"84","author":"Maddodi","year":"2008","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0045","doi-asserted-by":"crossref","first-page":"15055","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejpb.2023.02.002_b0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/CMR.0000000000000609","article-title":"Ultraviolet radiation and cutaneous melanoma: a historical perspective","volume":"30","author":"Autier","year":"2019","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjd.12492","article-title":"Emerging trends in the epidemiology of melanoma","volume":"170","author":"Nikolaou","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0065","first-page":"1071","article-title":"Cutaneous melanoma: from pathogenesis to therapy (review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jnci\/djy086","article-title":"Primary melanoma histologic subtype: impact on survival and response to therapy","volume":"111","author":"Lattanzi","year":"2019","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.ejpb.2023.02.002_b0075","doi-asserted-by":"crossref","unstructured":"M. Bobos, Histopathologic classification and prognostic factors of melanoma: a 2021 update, Ital J Dermatol Venerol, 156 (2021) 300-321. 10.23736\/s2784-8671.21.06958-3.","DOI":"10.23736\/S2784-8671.21.06958-3"},{"key":"10.1016\/j.ejpb.2023.02.002_b0080","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1002\/lary.26663","article-title":"Geographic region: does it matter in cutaneous melanoma of the head and neck?","volume":"127","author":"Kilic","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejpb.2023.02.002_b0085","doi-asserted-by":"crossref","unstructured":"F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68 (2018) 394-424. 10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"10.1016\/j.ejpb.2023.02.002_b0090","doi-asserted-by":"crossref","unstructured":"A.M. Goldstein, M. Chan, M. Harland, N.K. Hayward, F. Demenais, D.T. Bishop, E. Azizi, W. Bergman, G. Bianchi-Scarra, W. Bruno, D. Calista, L.A.C. Albright, V. Chaudru, A. Chompret, F. Cuellar, D.E. Elder, P. Ghiorzo, E.M. Gillanders, N.A. Gruis, J. Hansson, D. Hogg, E.A. Holland, P.A. Kanetsky, R.F. Kefford, M.T. Landi, J. Lang, S.A. Leachman, R.M. MacKie, V. Magnusson, G.J. Mann, J.N. Bishop, J.M. Palmer, S. Puig, J.A. Puig-Butille, M. Stark, H. Tsao, M.A. Tucker, L. Whitaker, E. Yakobson, L.M.S. Grp, M.G. Consortium, Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents, J Med Genet, 44 (2007) 99-106. 10.1136\/jmg.2006.043802.","DOI":"10.1136\/jmg.2006.043802"},{"key":"10.1016\/j.ejpb.2023.02.002_b0095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.0022-202x.2001.01421.x","article-title":"Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color","volume":"117","author":"Kennedy","year":"2001","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0100","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.3390\/jcm10163760","article-title":"Familial melanoma and susceptibility genes: a review of the most common clinical and dermoscopic phenotypic aspect, associated malignancies and practical tips for management","volume":"10","author":"Zocchi","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpb.2023.02.002_b0105","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4161\/cc.4.10.2026","article-title":"Analysis of BRAF mutation in primary and metastatic melanoma","volume":"4","author":"Libra","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejpb.2023.02.002_b0110","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-05-2720","article-title":"Oncogenic BRAF is required for tumor growth and maintenance in melanoma models","volume":"66","author":"Hoeflich","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0115","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/nm.2941","article-title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma","volume":"18","author":"Kwong","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2023.02.002_b0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.02.002_b0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10630","article-title":"A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma","volume":"480","author":"Yokoyama","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.02.002_b0130","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/ijc.22928","article-title":"EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis","volume":"121","author":"Rakosy","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0135","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cell.2006.06.008","article-title":"Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene","volume":"125","author":"Kim","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.02.002_b0140","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/sj.onc.1205859","article-title":"Roles of activated Src and Stat3 signaling in melanoma tumor cell growth","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ejpb.2023.02.002_b0145","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-05-2674","article-title":"Activation of Stat3 in human melanoma promotes brain metastasis","volume":"66","author":"Xie","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0150","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/srt.12350","article-title":"Non-invasive tools for the diagnosis of cutaneous melanoma","volume":"23","author":"Fink","year":"2017","journal-title":"Skin Res. Technol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0160","doi-asserted-by":"crossref","unstructured":"C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. Byrd, A.C. Buzaid, A.J. Cochran, D.G. Coit, S. Ding, A.M. Eggermont, K.T. Flaherty, P.A. Gimotty, J.M. Kirkwood, K.M. McMasters, M.C. Mihm, Jr., D.L. Morton, M.I. Ross, A.J. Sober, V.K. Sondak, Final version of 2009 AJCC melanoma staging and classification, J. Clin. Oncol., 27 (2009) 6199-6206. 10.1200\/JCO.2009.23.4799.","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"10.1016\/j.ejpb.2023.02.002_b0165","doi-asserted-by":"crossref","unstructured":"J.E. Gershenwald, R.A. Scolyer, K.R. Hess, V.K. Sondak, G.V. Long, M.I. Ross, A.J. Lazar, M.B. Faries, J.M. Kirkwood, G.A. McArthur, L.E. Haydu, A.M.M. Eggermont, K.T. Flaherty, C.M. Balch, J.F. Thompson, P. for members of the American Joint Committee on Cancer Melanoma Expert, D. the International Melanoma, P. Discovery, Melanoma staging: evidence-based changes in the american joint committee on cancer eighth edition cancer staging manual, CA Cancer J. Clin., 67 (2017) 472-492. 10.3322\/caac.21409.","DOI":"10.3322\/caac.21409"},{"key":"10.1016\/j.ejpb.2023.02.002_b0170","doi-asserted-by":"crossref","unstructured":"P. Gerami, S.S. Jewell, L.E. Morrison, B. Blondin, J. Schulz, T. Ruffalo, P.t. Matushek, M. Legator, K. Jacobson, S.R. Dalton, S. Charzan, N.A. Kolaitis, J. Guitart, T. Lertsbarapa, S. Boone, P.E. LeBoit, B.C. Bastian, Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma, Am. J. Surg. Pathol., 33 (2009) 1146-1156. 10.1097\/PAS.0b013e3181a1ef36.","DOI":"10.1097\/PAS.0b013e3181a1ef36"},{"key":"10.1016\/j.ejpb.2023.02.002_b0175","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/jid.2014.366","article-title":"Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma","volume":"135","author":"Siroy","year":"2015","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0180","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaad.2015.03.057","article-title":"Melanoma in situ: Part II. Histopathology, treatment, and clinical management","volume":"73","author":"Higgins","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0185","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4149\/neo_2016_403","article-title":"Malignant melanoma: diagnosis, treatment and cancer stem cells","volume":"63","author":"Kozovska","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.ejpb.2023.02.002_b0190","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11864-016-0421-5","article-title":"The promise of molecularly targeted and immunotherapy for advanced melanoma","volume":"17","author":"Margolin","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0195","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.02.002_b0200","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0205","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.22.00944","article-title":"Systemic therapy for melanoma: ASCO guideline rapid recommendation update","volume":"40","author":"Seth","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminoncol.2014.02.001","article-title":"Melanoma tumor cell heterogeneity: a molecular approach to study subpopulations expressing the embryonic morphogen nodal","volume":"41","author":"Seftor","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0215","doi-asserted-by":"crossref","unstructured":"J.q. Tang, X.y. Hou, C.s. Yang, Y.x. Li, Y. Xin, W.w. Guo, Z.p. Wei, Y.q. Liu, G. Jiang, Recent developments in nanomedicine for melanoma treatment, Int J Cancer, 141 (2017) 646-653. 10.1002\/ijc.30708.","DOI":"10.1002\/ijc.30708"},{"key":"10.1016\/j.ejpb.2023.02.002_b0220","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.biotechadv.2016.01.004","article-title":"Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy","volume":"34","author":"Brys","year":"2016","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejpb.2023.02.002_b0225","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2340\/00015555-2830","article-title":"Estimation of direct melanoma-related costs by disease stage and by phase of diagnosis and treatment according to clinical guidelines","volume":"98","author":"Buja","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0230","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"65","author":"Markman","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.02.002_b0235","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.02.002_b0240","doi-asserted-by":"crossref","unstructured":"R.B. Rigon, M.H. Oyafuso, A.T. Fujimura, M.L. Goncalez, A.H. do Prado, M.P. Gremiao, M. Chorilli, Nanotechnology-based drug delivery systems for melanoma antitumoral therapy: a review, Biomed Res Int, 2015 (2015) 841817. 10.1155\/2015\/841817.","DOI":"10.1155\/2015\/841817"},{"key":"10.1016\/j.ejpb.2023.02.002_b0245","first-page":"1002","article-title":"Latest news on nanotechnology for melanoma therapy and diagnosis","volume":"1","author":"Daga","year":"2016","journal-title":"SM J. Nanotechnol. Nanomed."},{"key":"10.1016\/j.ejpb.2023.02.002_b0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40204-017-0064-z","article-title":"Nanotechnology for the treatment of melanoma skin cancer","volume":"6","author":"Naves","year":"2017","journal-title":"Prog. Biomater."},{"key":"10.1016\/j.ejpb.2023.02.002_b0255","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00432-018-2726-1","article-title":"Melanoma treatment: from conventional to nanotechnology","volume":"144","author":"Mishra","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0260","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.colsurfb.2016.05.076","article-title":"Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma","volume":"146","author":"Labala","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2023.02.002_b0265","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fchem.2019.00167","article-title":"Gold nanoparticles for photothermal cancer therapy","volume":"7","author":"Vines","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejpb.2023.02.002_b0270","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-13-0259","article-title":"The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma","volume":"19","author":"Sheppard","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/pcmr.12646","article-title":"Melanocortin 1 receptor (MC1R) polymorphisms' influence on size and dermoscopic features of nevi","volume":"31","author":"Vallone","year":"2018","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0280","first-page":"717","article-title":"A population-based analysis of germline BAP1 mutations in melanoma","volume":"26","author":"O'Shea","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejpb.2023.02.002_b0285","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.2947","article-title":"POT1 loss-of-function variants predispose to familial melanoma","volume":"46","author":"Robles-Espinoza","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejpb.2023.02.002_b0290","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2023.02.002_b0295","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2023.02.002_b0300","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.02.002_b0305","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0310","first-page":"770","article-title":"Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling","volume":"2016","author":"Paluncic","year":"1863","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2023.02.002_b0315","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I - activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0320","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/PPO.0b013e31824d448c","article-title":"The role of the PI3K-AKT pathway in melanoma","volume":"18","author":"Davies","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.ejpb.2023.02.002_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.06.009","article-title":"Wnt\/\u03b2-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights","volume":"49","author":"Xue","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejpb.2023.02.002_b0330","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.3390\/ijms21144852","article-title":"WNT signaling in melanoma","volume":"21","author":"Gajos-Michniewicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.02.002_b0335","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jid.2017.07.839","article-title":"Gcc, STAT3 mediates nilotinib response in KIT-altered melanoma: a phase II multicenter trial of the French skin cancer network","volume":"138","author":"Delyon","year":"2018","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0340","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-005-1580-1","article-title":"Targeting STAT3 affects melanoma on multiple fronts","volume":"24","author":"Kortylewski","year":"2005","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejpb.2023.02.002_b0345","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s41374-019-0288-8","article-title":"Search for novel STAT3-dependent genes reveals SERPINA3 as a new STAT3 target that regulates invasion of human melanoma cells","volume":"99","author":"Kulesza","year":"2019","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ejpb.2023.02.002_b0350","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/gt.2013.35","article-title":"Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy","volume":"20","author":"Emeagi","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2023.02.002_b0355","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/ijms18030532","article-title":"Vanillin suppresses cell motility by inhibiting STAT3-mediated HIF-1alpha mRNA expression in malignant melanoma cells","volume":"18","author":"Park","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.02.002_b0360","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cbin.11134","article-title":"Knockdown of STAT3 targets a subpopulation of invasive melanoma stem-like cells","volume":"43","author":"Kulesza","year":"2019","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejpb.2023.02.002_b0365","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3389\/fonc.2014.00383","article-title":"Evaluating biomarkers in melanoma","volume":"4","author":"Karagiannis","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0370","first-page":"13","article-title":"Diagnostic and prognostic biomarkers in melanoma","volume":"7","author":"Weinstein","year":"2014","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0375","first-page":"89","article-title":"Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune, Biochim Biophys Acta Rev","volume":"1826","author":"van den Hurk","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0380","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15592294.2014.1003746","article-title":"Epigenetic regulation in human melanoma: past and future","volume":"10","author":"Sarkar","year":"2015","journal-title":"Epigenetics"},{"key":"10.1016\/j.ejpb.2023.02.002_b0385","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2017.10.006","article-title":"Epigenetics of malignant melanoma","volume":"51","author":"Moran","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0390","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cell.2012.07.033","article-title":"Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma","volume":"150","author":"Lian","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.02.002_b0395","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40291-018-0318-z","article-title":"Emerging biomarkers in cutaneous melanoma","volume":"22","author":"Eisenstein","year":"2018","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ejpb.2023.02.002_b0400","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.det.2012.04.011","article-title":"Radiation therapy for cutaneous melanoma","volume":"30","author":"Barker","year":"2012","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.ejpb.2023.02.002_b0405","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.addr.2017.09.016","article-title":"Targeted drug delivery to melanoma","volume":"127","author":"Liu","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.02.002_b0410","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/09546634.2013.813897","article-title":"Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2","volume":"25","author":"Ma","year":"2014","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.ejpb.2023.02.002_b0415","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1479-5876-8-115","article-title":"High activity of sequential low dose chemo-modulating temozolomide in combination with fotemustine in metastatic melanoma. A feasibility study","volume":"8","author":"Guida","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejpb.2023.02.002_b0420","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.855782","article-title":"Outcomes from cytotoxic chemotherapy following progression on immunotherapy in metastatic melanoma: an institutional case-series","volume":"12","author":"Gaughan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2021.11.022","article-title":"Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis","volume":"162","author":"Goldinger","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0430","doi-asserted-by":"crossref","unstructured":"G. Micali, F. Lacarrubba, M.R. Nasca, S. Ferraro, R.A. Schwartz, Topical pharmacotherapy for skin cancer: part II. Clinical applications, J Am Acad Dermatol, 70 (2014) P979.E971-979.E912. 10.1016\/j.jaad.2013.12.037.","DOI":"10.1016\/j.jaad.2013.12.037"},{"key":"10.1016\/j.ejpb.2023.02.002_b0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000496052","article-title":"Malignant melanoma treated with topical imiquimod: a bespoke treatment that spared the amputation","volume":"11","author":"Verga","year":"2019","journal-title":"Case Rep. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0440","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.4049\/jimmunol.1290060","article-title":"IFN-alpha in the treatment of melanoma","volume":"189","author":"Tarhini","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0445","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0450","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"43","author":"Franklin","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0455","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14737140.2017.1341315","article-title":"Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy","volume":"17","author":"O'Reilly","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejpb.2023.02.002_b0460","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0465","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejcsup.2013.07.011","article-title":"Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations","volume":"11","author":"Goldinger","year":"2013","journal-title":"EJC Suppl."},{"key":"10.1016\/j.ejpb.2023.02.002_b0470","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ejso.2016.10.014","article-title":"Developments in targeted therapy in melanoma","volume":"43","author":"Amann","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0475","first-page":"68","article-title":"BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients","volume":"22","author":"Mackiewicz","year":"2018","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.ejpb.2023.02.002_b0480","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.3390\/cancers12102801","article-title":"Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2023.02.002_b0485","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.2174\/0929867321666140716092512","article-title":"Nanoparticles in melanoma","volume":"21","author":"Berciano-Guerrero","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2023.02.002_b0490","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cbin.10459","article-title":"Effect of the surface modification, size, and shape on cellular uptake of nanoparticles","volume":"39","author":"Salatin","year":"2015","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejpb.2023.02.002_b0495","series-title":"Small Animal Clinical Pharmacology (Second Edition)","first-page":"27","article-title":"Chapter 2 - Clinical pharmacokinetics","author":"Maddison","year":"2008"},{"key":"10.1016\/j.ejpb.2023.02.002_b0500","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/polym10030267","article-title":"Chitosan and its derivatives for application in mucoadhesive drug delivery systems","volume":"10","author":"Ways","year":"2018","journal-title":"Polymers"},{"key":"10.1016\/j.ejpb.2023.02.002_b0505","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.nano.2014.05.007","article-title":"Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo","volume":"10","author":"Siddiqui","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2023.02.002_b0510","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1002\/jps.24548","article-title":"Orally administered chitosan-coated polycaprolactone nanoparticles containing curcumin attenuate metastatic melanoma in the lungs","volume":"104","author":"Loch-Neckel","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.02.002_b0515","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1042\/CS20160935","article-title":"Curcumin mediates anticancer effects by modulating multiple cell signaling pathways","volume":"131","author":"Kunnumakkara","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejpb.2023.02.002_b0520","doi-asserted-by":"crossref","first-page":"8587","DOI":"10.1038\/s41598-020-65468-1","article-title":"Curcumin encapsulated lecithin nanoemulsions: an oral platform for ultrasound mediated spatiotemporal delivery of curcumin to the tumor","volume":"10","author":"Prasad","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.02.002_b0525","series-title":"Medical Pharmacology and Therapeutics","first-page":"33","article-title":"Pharmacokinetics","author":"Waller","year":"2018"},{"key":"10.1016\/j.ejpb.2023.02.002_b0530","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2471\/BLT.10.079426","article-title":"Intradermal delivery of vaccines: potential benefits and current challenges","volume":"89","author":"Hickling","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ejpb.2023.02.002_b0535","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1039\/C9TB02175B","article-title":"Highly potent intradermal vaccination by an array of dissolving microneedle polypeptide cocktails for cancer immunotherapy","volume":"8","author":"Duong","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejpb.2023.02.002_b0540","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.biomaterials.2011.01.067","article-title":"Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery","volume":"32","author":"Zhang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.02.002_b0545","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1021\/acsnano.5b01042","article-title":"Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma","volume":"9","author":"Guo","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2023.02.002_b0550","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2016.02.035","article-title":"Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2Kb and H-2Db-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma","volume":"228","author":"Zhuang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.02.002_b0555","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.biomaterials.2018.02.033","article-title":"Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality","volume":"164","author":"Kang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.02.002_b0560","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ppap.201400071","article-title":"Anti-cancer therapies of 21st century: novel approach to treat human cancers using cold atmospheric plasma","volume":"11","author":"Ratovitski","year":"2014","journal-title":"Plasma Process Polym"},{"key":"10.1016\/j.ejpb.2023.02.002_b0565","doi-asserted-by":"crossref","first-page":"21974","DOI":"10.1038\/srep21974","article-title":"Synergistic effect of cold atmospheric plasma and drug loaded core-shell nanoparticles on inhibiting breast cancer cell growth","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2023.02.002_b0570","doi-asserted-by":"crossref","first-page":"15977","DOI":"10.18632\/oncotarget.13304","article-title":"Cold atmospheric plasma, a novel promising anti-cancer treatment modality","volume":"8","author":"Yan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejpb.2023.02.002_b0575","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12964-019-0360-4","article-title":"Cold atmospheric plasma and silymarin nanoemulsion synergistically inhibits human melanoma tumorigenesis via targeting HGF\/c-MET downstream pathway","volume":"17","author":"Adhikari","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.ejpb.2023.02.002_b0580","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"Bree","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.ejpb.2023.02.002_b0585","series-title":"Reference Module in Biomedical Sciences","article-title":"Routes of drug administration","author":"Bolger","year":"2018"},{"key":"10.1016\/j.ejpb.2023.02.002_b0590","doi-asserted-by":"crossref","first-page":"e23029","DOI":"10.1002\/bip.23029","article-title":"Inhibition of melanoma metastasis by dual-peptide PLGA NPS","volume":"108","author":"Arruda","year":"2017","journal-title":"Biopolymers"},{"key":"10.1016\/j.ejpb.2023.02.002_b0595","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/02652048.2018.1526340","article-title":"Bovine serum albumin nanoparticles improve the antitumour activity of curcumin in a murine melanoma model","volume":"35","author":"Camargo","year":"2018","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2023.02.002_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.110375","article-title":"Improved delivery of doxorubicin using rationally designed PEGylated platinum nanoparticles for the treatment of melanoma","volume":"108","author":"Mukherjee","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejpb.2023.02.002_b0605","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1021\/acsbiomaterials.9b01693","article-title":"Silver prussian blue analogue nanoparticles: rationally designed advanced nanomedicine for multifunctional biomedical applications","volume":"6","author":"Mukherjee","year":"2020","journal-title":"ACS Biomater Sci. Eng."},{"key":"10.1016\/j.ejpb.2023.02.002_b0610","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s11095-010-0360-y","article-title":"Intratumoral drug delivery with nanoparticulate carriers","volume":"28","author":"Holback","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0615","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.3390\/ijms21124493","article-title":"Intratumoral administration of a novel cytotoxic formulation with strong tissue dispersive properties regresses tumor growth and elicits systemic adaptive immunity in in vivo models","volume":"21","author":"Bender","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.02.002_b0620","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1038\/cddis.2013.314","article-title":"Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria","volume":"4","author":"Wang","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejpb.2023.02.002_b0625","first-page":"2641","article-title":"Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells","volume":"7","author":"Wang","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.02.002_b0630","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/IJN.S130753","article-title":"Cuprous oxide nanoparticle-inhibited melanoma progress by targeting melanoma stem cells","volume":"12","author":"Yu","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.02.002_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2020.101846","article-title":"Photothermal\/sonodynamic therapy of melanoma tumor by a gold\/manganese dioxide nanocomposite: in vitro and in vivo studies","volume":"31","author":"Soratijahromi","year":"2020","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"10.1016\/j.ejpb.2023.02.002_b0640","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.1016\/j.biomaterials.2014.05.049","article-title":"Pluronic-encapsulated natural chlorophyll nanocomposites for in vivo cancer imaging and photothermal\/photodynamic therapies","volume":"35","author":"Chu","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.02.002_b0645","doi-asserted-by":"crossref","first-page":"24381","DOI":"10.3402\/nano.v5.24381","article-title":"Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanoma","volume":"5","author":"Monge-Fuentes","year":"2014","journal-title":"Nano Rev"},{"key":"10.1016\/j.ejpb.2023.02.002_b0650","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jphotobiol.2016.12.002","article-title":"Photodynamic therapy mediated by acai oil (Euterpe oleracea Martius) in nanoemulsion: A potential treatment for melanoma","volume":"166","author":"Monge-Fuentes","year":"2017","journal-title":"J. Photochem. Photobiol. B"},{"key":"10.1016\/j.ejpb.2023.02.002_b0655","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2174\/0929867324666171009120154","article-title":"Recent advances and perspectives in liposomes for cutaneous drug delivery","volume":"25","author":"Carita","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2023.02.002_b0660","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2147\/IJN.S147759","article-title":"Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy","volume":"13","author":"Duan","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.02.002_b0665","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.colsurfb.2011.02.038","article-title":"Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel","volume":"85","author":"Liu","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2023.02.002_b0670","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2014.09.005","article-title":"Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression","volume":"194","author":"Shi","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.02.002_b0675","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/biom10020285","article-title":"Silencing of STAT3 via peptidomimetic LNP-mediated systemic delivery of RNAi downregulates PD-L1 and inhibits melanoma growth","volume":"10","author":"Ehexige","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejpb.2023.02.002_b0680","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/10408347.2018.1456315","article-title":"A Critical Review of Properties and Analytical Methods for the Determination of Docetaxel in Biological and Pharmaceutical Matrices","volume":"48","author":"da Silva","year":"2018","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.ejpb.2023.02.002_b0685","doi-asserted-by":"crossref","first-page":"7638","DOI":"10.1021\/acsami.5b12144","article-title":"Design of highly potent lipid-functionalized peptidomimetics for efficient in vivo siRNA Delivery","volume":"8","author":"Xiao","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2023.02.002_b0690","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.3390\/molecules24183413","article-title":"Design of peptidomimetic functionalized cholesterol based lipid nanoparticles for efficient delivery of therapeutic nucleic acids","volume":"24","author":"Ehexige","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2023.02.002_b0695","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/jps.24291","article-title":"Tumor-targeted paclitaxel delivery and enhanced penetration using TAT-decorated liposomes comprising redox-responsive poly(ethylene glycol)","volume":"104","author":"Fu","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.02.002_b0700","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jconrel.2018.08.011","article-title":"Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity","volume":"286","author":"Gu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.02.002_b0705","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biomaterials.2018.10.022","article-title":"Gemcitabine nanoparticles promote antitumor immunity against melanoma","volume":"189","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.02.002_b0710","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ijc.28449","article-title":"Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts","volume":"134","author":"Maenhout","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0715","first-page":"2985","article-title":"Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy","volume":"10","author":"Xiong","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.02.002_b0720","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2016.01.044","article-title":"Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation","volume":"231","author":"Li","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.02.002_b0725","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3389\/fbioe.2020.00495","article-title":"Pre-treatment with PLGA\/silibinin nanoparticles mitigates dacarbazine-induced hepatotoxicity","volume":"8","author":"Durymanov","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejpb.2023.02.002_b0730","doi-asserted-by":"crossref","first-page":"108624","DOI":"10.18632\/oncotarget.20585","article-title":"Improving anti-melanoma effect of curcumin by biodegradable nanoparticles","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejpb.2023.02.002_b0735","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nano.2017.12.017","article-title":"Redox-responsive micelles from disulfide bond-bridged hyaluronic acid-tocopherol succinate for the treatment of melanoma","volume":"14","author":"Xia","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2023.02.002_b0740","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.carbpol.2017.12.047","article-title":"Redox\/enzyme sensitive chondroitin sulfate-based self-assembled nanoparticles loading docetaxel for the inhibition of metastasis and growth of melanoma","volume":"184","author":"Liu","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2023.02.002_b0745","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.1021\/nn100870z","article-title":"Attenuation of mouse melanoma by A\/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells","volume":"4","author":"Rachakatla","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2023.02.002_b0750","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1016\/j.actbio.2012.04.042","article-title":"Multifunctional particles for melanoma-targeted drug delivery","volume":"8","author":"Wadajkar","year":"2012","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2023.02.002_b0755","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acs.molpharmaceut.9b00047","article-title":"Tumor targeting by peptide-decorated gold nanoparticles","volume":"16","author":"Albertini","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.02.002_b0760","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","article-title":"Integrins as therapeutic targets","volume":"33","author":"Goodman","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejpb.2023.02.002_b0765","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.2147\/IJN.S250549","article-title":"A pH-sensitive prodrug nanocarrier based on diosgenin for doxorubicin delivery to efficiently inhibit tumor metastasis","volume":"15","author":"Wei","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2023.02.002_b0770","doi-asserted-by":"crossref","first-page":"1703969","DOI":"10.1002\/adma.201703969","article-title":"Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity","volume":"29","author":"Kroll","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejpb.2023.02.002_b0775","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.biomaterials.2013.12.079","article-title":"Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma","volume":"35","author":"Siu","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.02.002_b0780","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijpharm.2017.03.087","article-title":"Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles","volume":"525","author":"Labala","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.02.002_b0785","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/pharmaceutics10040214","article-title":"Nanoemulsion as a platform for iontophoretic delivery of lipophilic drugs in skin tumors","volume":"10","author":"Dalmolin","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.02.002_b0790","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1208\/s12249-017-0833-y","article-title":"Effective skin cancer treatment by topical co-delivery of curcumin and STAT3 siRNA using cationic liposomes","volume":"19","author":"Jose","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2023.02.002_b0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2018.08.013","article-title":"Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin","volume":"182","author":"Zou","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2023.02.002_b0800","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.biopha.2015.05.002","article-title":"Improved anti-melanoma effect of a transdermal mitoxantrone ethosome gel","volume":"73","author":"Yu","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2023.02.002_b0805","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.colsurfb.2018.11.018","article-title":"pH responsive 5-fluorouracil loaded biocompatible nanogels for topical chemotherapy of aggressive melanoma","volume":"174","author":"Sahu","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejpb.2023.02.002_b0810","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2020.03.023","article-title":"Transdermal siRNA delivery by pH-switchable micelles with targeting effect suppress skin melanoma progression","volume":"322","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.02.002_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119626","article-title":"Paclitaxel skin delivery by micelles-embedded Carbopol 940 hydrogel for local therapy of melanoma","volume":"587","author":"Xu","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.02.002_b0820","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41467-019-09029-9","article-title":"Framework nucleic acids as programmable carrier for transdermal drug delivery","volume":"10","author":"Wiraja","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2023.02.002_b0825","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.1021\/acsami.7b18293","article-title":"Au nanocage-strengthened dissolving microneedles for chemo-photothermal combined therapy of superficial skin tumors","volume":"10","author":"Dong","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2023.02.002_b0830","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.7150\/thno.44194","article-title":"Dissolving microneedles with spatiotemporally controlled pulsatile release nanosystem for synergistic chemo-photothermal therapy of melanoma","volume":"10","author":"Qin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejpb.2023.02.002_b0835","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.24720","article-title":"A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma","volume":"116","author":"Hersh","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0840","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.25659","article-title":"A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)","volume":"117","author":"Kottschade","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0845","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.27760","article-title":"A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775","volume":"119","author":"Kottschade","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2023.02.002_b0850","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.02.002_b0855","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","article-title":"Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors","volume":"22","author":"Von Hoff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2023.02.002_b0860","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jdv.15925","article-title":"Ablative fractional laser-assisted photodynamic therapy for lentigo maligna: a prospective pilot study","volume":"34","author":"R\u00e4s\u00e4nen","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:52:26Z","timestamp":1760547146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":172,"alternative-id":["S0939641123000346"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.002","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanodelivery systems for cutaneous melanoma treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}